AI
TEVA icon

Axiom Investors’s Teva Pharmaceuticals TEVA Stock Holding History

Axiom Investors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,173,807
Closed -$33.4M – 151
2025
Q1 		$33.4M Buy
+2,173,807
New +$38.8M 0.32% 47
2016
Q3 		– Sell
-624,750
Closed -$31.4M – 160
2016
Q2 		$31.4M Sell
624,750
-551,009
-47% -$29.3M 0.91% 42
2016
Q1 		$62.9M Sell
1,175,759
-382,479
-25% -$22.4M 1.96% 16
2015
Q4 		$102M Sell
1,558,238
-376,969
-19% -$23.3M 3.3% 5
2015
Q3 		$109M Buy
1,935,207
+443,614
+30% +$28.8M 3.45% 6
2015
Q2 		$88.2M Sell
1,491,593
-55,345
-4% -$3.41M 2.53% 11
2015
Q1 		$96.4M Buy
1,546,938
+882,205
+133% +$51.3M 2.61% 8
2014
Q4 		$38.2M Buy
+664,733
New +$37M 0.94% 47

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Axiom Investors's TEVA Position: Q2 2025 in Review

Axiom Investors sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 2,173,807 shares — an estimated $33.4M sold.

Axiom Investors first reported a position in TEVA in Q4 2014 and held it in 8 quarters. The position peaked at $109M in Q3 2015. 540 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Axiom Investors reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Axiom Investors sold 2,173,807 Teva Pharmaceuticals shares in Q2 2025, an estimated $33.4M.
  • Axiom Investors first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 8 quarters.
  • Axiom Investors's Teva Pharmaceuticals position peaked at $109M in Q3 2015.
  • 540 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Axiom Investors's 13F filing for Q2 2025, filed 7 Aug 2025.